In this landscape it means claims tied to biocompatible substrates, antimicrobial or hydrophilic coatings, or flexible insertion-tube construction, layered on top of core endoscope structure claims under A61B1/00. It excludes patents that describe only the mechanical or optical function of an endoscope without a material-specific limitation. The search also pulls in A61L29 and A61L31, the classification codes specifically covering coating materials and body-contact implant materials, to catch coating-only filings that might not mention 'endoscope' prominently.

Filings rose from 50 in 2017 to a peak of 67 in 2023, but the 2022 midpoint of 60 was already close to that peak, indicating the growth had slowed well before the top. This pattern typically means the core claim territory — basic coating chemistries and standard insertion-tube materials — is largely occupied, pushing new filers toward narrower, more defensive claims rather than broad foundational ones. It does not mean R&D activity has stopped, only that it is being expressed in smaller, more specific claim increments.

The United States receives by far the largest share of filings in this corpus at 508 records, well ahead of the EPO at 264 and WIPO/PCT at 140. If your commercial strategy includes the US market, filing there directly (rather than relying solely on a PCT route) puts you in the same jurisdiction as the majority of existing prior art, which matters for both examination context and competitive monitoring. Smaller volumes at the Australian and Canadian offices suggest those markets carry comparatively lighter prior art density.

Not necessarily. Citation counts accumulate over time within a searched corpus, so older records such as those from the mid-2000s naturally collect more citations simply by being available longer for later filings to reference. A highly cited patent tells you it shaped how later claims were drafted, which is a useful signal for understanding the field's technical lineage, but it does not tell you whether the patent is still in force or whether its specific claims still block current product designs — that requires a separate legal-status and claim-scope check.

The classification data points toward the smaller IPC subclasses — A61L (sterilising and disinfecting, 58 records), A61F (implants, 37 records) and A61N (electrotherapy overlap, 15 records) — as comparatively lightly filed relative to the dominant A61B subclass with 1,130 records. Specific combinations, such as antimicrobial coatings validated for repeated sterilisation cycles or hydrophilic coating adhesion at flexible-joint interfaces, sit in this thinner territory. Any first claim written there should be checked against the handful of existing A61L/A61F filings before drafting, since low volume does not mean zero prior art.